Incident Herpes Zoster and Risk of Dementia

Background and Objectives Herpes zoster (HZ) is caused by reactivation of the neurotrophic varicella-zoster virus (VZV). Zoster may contribute to development of dementia through neuroinflammation, cerebral vasculopathy, or direct neural damage, but epidemiologic evidence is limited. We used data from linked nationwide Danish registries to conduct a cohort study of the association between zoster and dementia during 1997–2017. As secondary aims, we examined whether associations were more pronounced for zoster involving cranial nerves (mainly ophthalmic zoster) or the CNS and Alzheimer disease as an outcome. Methods We included people aged ≥40 years with zoster and a general population comparison cohort matched 5:1 by sex and birth year. We identified zoster and dementia in the registries using prescription records in the community and hospital diagnoses. We used Cox regression to compute confounder-adjusted hazard ratios (HRs) with 95% CIs for dementia associated with zoster during 0–1 year and 1–21 years of follow-up. We compared the cumulative incidence of dementia, inverse probability weighted for confounders. Results The study included 247,305 people with zoster and 1,235,890 matched general population comparators (median age 64 years; 61% female). The HR of all-cause dementia was 0.98 (95% CI 0.92–1.04) during the first year and 0.93 (95% CI 0.90–0.95) thereafter in people with zoster vs matched comparators. Dementia was diagnosed in 9.7% of patients with zoster and 10.3% of matched comparators by the end of follow-up. We observed no increased long-term risk of dementia in subgroup analyses, except possibly in people with CNS infection (HR 1.94; 95% CI 0.78–4.80). Analyses of Alzheimer disease as a separate outcome showed similar results. Discussion HZ is not associated with an increased risk of dementia, and contrary to expectation, we found a small decrease in the risk. The explanation for this finding is unclear, and systematic errors should be considered. Patients with CNS involvement had an almost 2-fold increased relative risk of dementia. The population attributable fraction of dementia due to this rare complication is estimated at 0.014%. Therefore, universal vaccination against VZV in the elderly is unlikely to reduce dementia risk.

[1]  T. Wiemken,et al.  Impact of herpes zoster vaccination on incident dementia: A retrospective study in two patient cohorts , 2021, PloS one.

[2]  K. Muir,et al.  Shingles, Zostavax vaccination and risk of developing dementia: a nested case–control study—results from the UK Biobank cohort , 2021, BMJ Open.

[3]  S. Langan,et al.  Associations of Lifestyle and Anthropometric Factors With the Risk of Herpes Zoster: A Nationwide Population-Based Cohort Study , 2021, American journal of epidemiology.

[4]  S. Langan,et al.  Perceived psychological stress and risk of herpes zoster: a nationwide population‐based cohort study , 2021, The British journal of dermatology.

[5]  R. Dessau,et al.  Characteristics and long-term prognosis of Danish patients with varicella zoster virus detected in the cerebrospinal fluid, compared with the background population. , 2021, The Journal of infectious diseases.

[6]  Jae-Sung Lim,et al.  Herpes Zoster Does Not Increase the Risk of Neurodegenerative Dementia: A Case-Control Study , 2021, American journal of Alzheimer's disease and other dementias.

[7]  G. Waldemar,et al.  Antiherpetic medication and incident dementia: Observational cohort studies in four countries , 2020, medRxiv.

[8]  K. Blennow,et al.  Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study , 2020, Scientific Reports.

[9]  Naaheed Mukadam,et al.  Dementia prevention, intervention, and care: 2020 report of the Lancet Commission , 2020, The Lancet.

[10]  Joon Seo Lim,et al.  Association of herpes zoster with dementia and effect of antiviral therapy on dementia: a population-based cohort study , 2020, European Archives of Psychiatry and Clinical Neuroscience.

[11]  R. Cohrs,et al.  Varicella Zoster Virus Infection of Primary Human Spinal Astrocytes Produces Intracellular Amylin, Amyloid-beta, and an Amyloidogenic Extracellular Environment. , 2019, The Journal of infectious diseases.

[12]  G. Waldemar,et al.  Declining incidence of dementia: A national registry-based study over 20 years , 2019, Alzheimer's & Dementia.

[13]  L. Smeeth,et al.  Human herpesvirus infections and dementia or mild cognitive impairment: a systematic review and meta-analysis , 2019, Scientific Reports.

[14]  A. Milstein,et al.  Stress Disorders and Dementia in the Danish Population , 2019, American journal of epidemiology.

[15]  Timothy Y. Huang,et al.  Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer’s disease –conformist, nonconformist, and realistic prospects for AD pathogenesis , 2018, Translational Neurodegeneration.

[16]  L. Smeeth,et al.  Association of herpesviruses and stroke: Systematic review and meta-analysis , 2018, PloS one.

[17]  Rudolph E. Tanzi,et al.  Alzheimer’s Disease-Associated β-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection , 2018, Neuron.

[18]  L. Smeeth,et al.  Inequalities in zoster disease burden: a population‐based cohort study to identify social determinants using linked data from the U.K. Clinical Practice Research Datalink , 2018, British Journal of Dermatology.

[19]  D. Altman,et al.  Population attributable fraction , 2018, British Medical Journal.

[20]  M. Gossop,et al.  Herpes Zoster and Dementia: A Nationwide Population-Based Cohort Study. , 2017, The Journal of clinical psychiatry.

[21]  Herng‐Ching Lin,et al.  Increased risk of dementia following herpes zoster ophthalmicus , 2017, PloS one.

[22]  Mogens Vestergaard,et al.  Prevaccination epidemiology of herpes zoster in Denmark: Quantification of occurrence and risk factors. , 2017, Vaccine.

[23]  A. Easton,et al.  Increased rates of sequelae post-encephalitis in individuals attending primary care practices in the United Kingdom: a population-based retrospective cohort study , 2017, Journal of Neurology.

[24]  L. Steardo,et al.  Targeting neuroinflammation in Alzheimer’s disease , 2016, Journal of inflammation research.

[25]  H. Sørensen,et al.  Data Resource Profile: The Danish National Prescription Registry , 2016, International journal of epidemiology.

[26]  Anke Neumann,et al.  Covariate adjustment of cumulative incidence functions for competing risks data using inverse probability of treatment weighting , 2016, Comput. Methods Programs Biomed..

[27]  Sigrun Alba Johannesdottir Schmidt,et al.  The Danish National Patient Registry: a review of content, data quality, and research potential , 2015, Clinical epidemiology.

[28]  D. Hanley,et al.  Herpes Simplex Encephalitis: Lack of Clinical Benefit of Long-term Valacyclovir Therapy. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  Henrik Toft Sørensen,et al.  The Danish Civil Registration System as a tool in epidemiology , 2014, European Journal of Epidemiology.

[30]  A. Nordlund,et al.  Cognitive impairment 3 years after neurological Varicella-zoster virus infection: a long-term case control study , 2013, Journal of Neurology.

[31]  G. Waldemar,et al.  Overdiagnosis of Dementia in Young Patients – A Nationwide Register-Based Study , 2012, Dementia and Geriatric Cognitive Disorders.

[32]  Anna M Z Gagliardi,et al.  Vaccines for preventing herpes zoster in older adults , 2012, The Cochrane database of systematic reviews.

[33]  V. Vaillant,et al.  Long-term outcome of patients presenting with acute infectious encephalitis of various causes in France. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  M. Alonso,et al.  Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells , 2012, Journal of neuroscience research.

[35]  R. Nussinov,et al.  Antimicrobial properties of amyloid peptides. , 2012, Molecular pharmaceutics.

[36]  O. Mors,et al.  The Danish Psychiatric Central Research Register , 2011, Scandinavian journal of public health.

[37]  Marianne Lundkjær Gjerstorff,et al.  The Danish Cancer Registry , 2011, Scandinavian journal of public health.

[38]  Paul D. Griffiths,et al.  Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[39]  R. Cohrs,et al.  Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment , 2009, The Lancet Neurology.

[40]  L. Kessing,et al.  Validity of Dementia Diagnoses in the Danish Hospital Registers , 2007, Dementia and Geriatric Cognitive Disorders.

[41]  N. Lautenschlager,et al.  Dementia associated with infectious diseases , 2005, International Psychogeriatrics.

[42]  O. Salonen,et al.  Subcortical type cognitive impairment in herpes zoster encephalitis , 1997, Journal of Neurology.

[43]  S. Lehrer,et al.  Herpes Zoster Vaccination Reduces Risk of Dementia , 2021, In Vivo.

[44]  R. Juan Sociodemographic characteristics and chronic medical conditions as risk factors for herpes zoster A population-based study from primary care in Madrid (Spain) , 2014 .

[45]  Miguel A Hernán,et al.  The hazards of hazard ratios. , 2010, Epidemiology.

[46]  M. Rowbotham,et al.  Recommendations for the management of herpes zoster. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.